Sophion Bioscience, CreaCell demonstrate performances of HEK-hKir2.1 cells on QPatch HT

Denmark-based Sophion Bioscience and France-based CreaCell have successfully demonstrated the performances of HEK-hKir2.1 cells on QPatch HT. Inward rectifier potassium channels of the Kir2 subfamily are important determinants of the electrical activity of cardiac cells, and mutations of the Kir2.1 channels are associated with familial atrial fibrillation, Andersen-Tawil syndrome and short-QT syndrome.

Because human Kir2.1 is a relevant target in preclinical cardiac safety testing of drug compounds, Sophion Bioscience and CreaCell demonstrate the functionality of the CreaCell’s HEK-hKir2.1 recombinant cell line on Sophion’s automated patch-clamp system QPatch HT. Current amplitudes, IV curves, Ba2+ currents, and chloroethylclonidine dose-response curves were analysed.

“Several of our customers have asked us for a QPatch-optimised cell line expressing clinically relevant hKir2.1 ion channels. We are pleased to announce the first result of this fruitful collaboration with CreaCell and our customers will benefit,” said Dr Morten Sunesen, VP of Customer Relations at Sophion.

“The synergy between our two companies is natural and allows us to satisfy client demands. At the same time, through this partnership with Sophion and its extensive network of customers, CreaCell confirms its intentions of developing its position in the worldwide market,” said Dr Pierre-Yves Perche, Chief Executive Officer, CreaCell.

EP News Bureau – Mumbai